Abstract The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by
genetic alterations in upstream signaling molecules such as receptor tyrosine kinases …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm and was the first
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …

Although gene fusions have been recognized as important drivers of cancer for decades,
our understanding of the prevalence and function of gene fusions has been revolutionized …

Cysteine metabolism plays a critical role in cancer cell survival. Cysteine depletion was
reported to inhibit tumor growth and induce pancreatic cancer cell ferroptosis. Nevertheless …

The development of inhibitors against Abl has changed the landscape for the treatment of
chronic myelogenous leukemia (CML) and cancer in general. Beginning with the …

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of patients with chronic
myeloid leukemia (CML). However, continued use of these inhibitors has contributed to the …

The natural phenomenon of drug resistance is a widespread issue that hampers the
performance of drugs in many major clinical indications. Antibacterial and antifungal drugs …

We recently reported that chronic myeloid leukaemia (CML) patients harbour high levels of
STAT5 when they progress to advanced phases of disease. Advanced disease is …

Abstract Imatinib mesylate (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly referred
to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents …

Protein kinases play key roles in oncogenic signaling and are a major focus in the
development of targeted cancer therapies. Imatinib, a BCR-Abl tyrosine kinase inhibitor, is a …